244 related articles for article (PubMed ID: 11082718)
1. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin-based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression.
Suzuki K; Matsumoto K; Hashimoto K; Kurokawa K; Jinbo S; Suzuki T; Imai K; Yamanaka H; Kawashima K; Takahashi H
Hinyokika Kiyo; 1995 Oct; 41(10):775-80. PubMed ID: 8533673
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
5. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
7. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
10. [Carboplatin in pediatrics].
Doz F
Bull Cancer; 2000 Aug; 87 Spec No():25-9. PubMed ID: 11082719
[TBL] [Abstract][Full Text] [Related]
11. [Dose individualization for carboplatin in cancer chemotherapy].
Oudard S; Lauraine EP
Bull Cancer; 1997 Jun; 84(6):675-7. PubMed ID: 9295872
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of combretastatin a-4 phosphate with carboplatin.
Bilenker JH; Flaherty KT; Rosen M; Davis L; Gallagher M; Stevenson JP; Sun W; Vaughn D; Giantonio B; Zimmer R; Schnall M; O'Dwyer PJ
Clin Cancer Res; 2005 Feb; 11(4):1527-33. PubMed ID: 15746056
[TBL] [Abstract][Full Text] [Related]
13. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
14. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant.
Colby C; Koziol S; McAfee SL; Yeap B; Spitzer TR
Bone Marrow Transplant; 2002 Mar; 29(6):467-72. PubMed ID: 11960264
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's].
Nakamura T; Onishi Y; Kono T; Maeda T; Wada T; Hatae M
Gan To Kagaku Ryoho; 1997 Mar; 24(5):579-83. PubMed ID: 9087291
[TBL] [Abstract][Full Text] [Related]
17. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
18. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
19. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.
Watanabe M; Aoki Y; Tomita M; Sato T; Takaki Y; Kato N; Kikuchi M; Kase H; Tanaka K
Gynecol Oncol; 2002 Feb; 84(2):335-8. PubMed ID: 11812097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
